These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 37252163)

  • 1. Efficacy and safety of topical cyclosporine 0.1% in moderate-to-severe dry eye disease refractory to topical cyclosporine 0.05% regimen.
    Chan YH; Sun CC
    Taiwan J Ophthalmol; 2023; 13(1):68-74. PubMed ID: 37252163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One-Year Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease.
    Baudouin C; de la Maza MS; Amrane M; Garrigue JS; Ismail D; Figueiredo FC; Leonardi A
    Eur J Ophthalmol; 2017 Nov; 27(6):678-685. PubMed ID: 28708219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistence of Efficacy of 0.1% Cyclosporin A Cationic Emulsion in Subjects with Severe Keratitis Due to Dry Eye Disease: A Nonrandomized, Open-label Extension of the SANSIKA Study.
    Labetoulle M; Leonardi A; Amrane M; Ismail D; Garrigue JS; Garhöfer G; de la Maza MS; Baudouin C
    Clin Ther; 2018 Nov; 40(11):1894-1906. PubMed ID: 30389343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Switching from Cyclosporine A 0.05% Anionic Emulsion to Cyclosporine A 0.1% Cationic Emulsion in Patients with Dry Eye Associated with Sjögren's Syndrome.
    Kim J; Moon TK; Yoon HJ; Ji YS; Yoon KC
    J Ocul Pharmacol Ther; 2021 Oct; 37(8):472-478. PubMed ID: 34449255
    [No Abstract]   [Full Text] [Related]  

  • 5. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group.
    Sall K; Stevenson OD; Mundorf TK; Reis BL
    Ophthalmology; 2000 Apr; 107(4):631-9. PubMed ID: 10768324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies.
    Leonardi A; Messmer EM; Labetoulle M; Amrane M; Garrigue JS; Ismail D; Sainz-de-la-Maza M; Figueiredo FC; Baudouin C
    Br J Ophthalmol; 2019 Jan; 103(1):125-131. PubMed ID: 29545413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial.
    Leonardi A; Van Setten G; Amrane M; Ismail D; Garrigue JS; Figueiredo FC; Baudouin C
    Eur J Ophthalmol; 2016 Jun; 26(4):287-96. PubMed ID: 27055414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye.
    Baudouin C; Figueiredo FC; Messmer EM; Ismail D; Amrane M; Garrigue JS; Bonini S; Leonardi A
    Eur J Ophthalmol; 2017 Aug; 27(5):520-530. PubMed ID: 28362054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of a new topical cationic emulsion of cyclosporine A on dry eye clinical signs in an experimental mouse model of dry eye.
    Daull P; Feraille L; Barabino S; Cimbolini N; Antonelli S; Mauro V; Garrigue JS
    Exp Eye Res; 2016 Dec; 153():159-164. PubMed ID: 27777121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of 0.05% cyclosporine ophthalmic emulsion in treatment of Chinese patients with moderate to severe dry eye disease: A 12-week, multicenter, randomized, double-masked, placebo-controlled phase III clinical study.
    Chen D; Zhang S; Bian A; Hong J; Deng Y; Zhang M; Chen W; Shao Y; Zhao J
    Medicine (Baltimore); 2019 Aug; 98(31):e16710. PubMed ID: 31374063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in post-refractive surgery chronic dry eye patients with ocular pain.
    Zhao L; Chen J; Duan H; Yang T; Ma B; Zhou Y; Bian L; Cai X; Qi H
    BMC Ophthalmol; 2024 Jan; 24(1):28. PubMed ID: 38247010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical ocular 0.1% cyclosporine A cationic emulsion in dry eye disease patients with severe keratitis: experience through the French early-access program.
    Pisella PJ; Labetoulle M; Doan S; Cochener-Lamard B; Amrane M; Ismail D; Creuzot-Garcher C; Baudouin C
    Clin Ophthalmol; 2018; 12():289-299. PubMed ID: 29440872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Multicenter, Randomized, Double-Blind Evaluation of the Efficacy of TJO-087 Versus 0.05% Cyclosporine A in Moderate to Severe Dry Eye.
    Eom Y; Yoon KC; Kim HK; Song JS; Hyon JY; Kim HM
    J Ocul Pharmacol Ther; 2023; 39(1):27-35. PubMed ID: 36450107
    [No Abstract]   [Full Text] [Related]  

  • 14. Real-world insights and outcomes related to ciclosporin A 0.1% cationic emulsion for the long-term treatment of dry eye disease in Germany: Country-level sub-analysis of the PERSPECTIVE study.
    Lanzl I; Deuter CME; Lorenz K; Geerling G;
    Graefes Arch Clin Exp Ophthalmol; 2024 Oct; 262(10):3261-3271. PubMed ID: 38722320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamin B12 deficiency evaluation and treatment in severe dry eye disease with neuropathic ocular pain.
    Ozen S; Ozer MA; Akdemir MO
    Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1173-1177. PubMed ID: 28299439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Randomized, Controlled Trial Comparing Tearcare
    Ayres BD; Bloomenstein MR; Loh J; Chester T; Saenz B; Echegoyen J; Kannarr SR; Perez VL; Rodriguez TC; Dickerson JE
    Clin Ophthalmol; 2023; 17():3925-3940. PubMed ID: 38143559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation Between the Inflammatory Marker HLA-DR and Signs and Symptoms in Moderate to Severe Dry Eye Disease.
    Brignole-Baudouin F; Riancho L; Ismail D; Deniaud M; Amrane M; Baudouin C
    Invest Ophthalmol Vis Sci; 2017 Apr; 58(4):2438-2448. PubMed ID: 28448672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease.
    Wirta DL; Torkildsen GL; Moreira HR; Lonsdale JD; Ciolino JB; Jentsch G; Beckert M; Ousler GW; Steven P; Krösser S
    Ophthalmology; 2019 Jun; 126(6):792-800. PubMed ID: 30703441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the effect of cyclosporine-A 0.05% emulsion on the ocular surface and corneal sensation following cataract surgery.
    Hamada S; Moore TC; Moore JE; Al-Dreihi MG; Anbari A; Shah S
    Cont Lens Anterior Eye; 2016 Feb; 39(1):15-9. PubMed ID: 26275686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twelve-Month Results of Cyclosporine A Cationic Emulsion in a Randomized Study in Patients With Pediatric Vernal Keratoconjunctivitis.
    Bremond-Gignac D; Doan S; Amrane M; Ismail D; Montero J; Németh J; Aragona P; Leonardi A;
    Am J Ophthalmol; 2020 Apr; 212():116-126. PubMed ID: 31770513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.